144690-07-3

Basic information

• Product Name: OlMesartan interMediate iMpurity II
• Synonyms: OlMesartan interMediate iMpurity II;1H-IMidazole-4-carboxylic acid, 5-acetyl-2-propyl-, ethyl ester;Olmesartan intermediate impurity Ⅰ;4-ACETYL-2-PROPYL-1H-IMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER;5-Acetyl-2-propyl-1H-Imidazole-4-carboxylic Acid Ethyl Ester;Ethyl 4-acetyl-2-propyl-1H-imidazole-5-carboxylate;Olmesartan Medoxomil Impurity 6
• CAS NO: 144690-07-3
• Molecular Formula: C₁₁H₁₆N₂O₃
• Molecular Weight: 224.25634
• Mol File: 144690-07-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 438.5±30.0 °C(Predicted)
• Appearance: /
• Density: 1.142±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 9.05±0.10(Predicted)
• CAS DataBase Reference: OlMesartan interMediate iMpurity II(CAS DataBase Reference)
• NIST Chemistry Reference: OlMesartan interMediate iMpurity II(144690-07-3)
• EPA Substance Registry System: OlMesartan interMediate iMpurity II(144690-07-3)

Safety Data

• Hazardous Substances Data: 144690-07-3(Hazardous Substances Data)

Usage

Description

OlMesartan interMediate iMpurity II is an intermediate compound used in the synthesis of Olmesartan, a medication belonging to the class of angiotensin II receptor blockers (ARBs). It plays a crucial role in the development of antihypertensive drugs, helping to manage high blood pressure and other cardiovascular conditions.

Uses

Used in Pharmaceutical Industry:
OlMesartan interMediate iMpurity II is used as a synthetic intermediate for the production of Olmesartan, an angiotensin II receptor blocker. It is essential in the development of antihypertensive drugs that help manage high blood pressure and other cardiovascular conditions by blocking the action of angiotensin II, a hormone responsible for narrowing blood vessels.
Additionally, OlMesartan interMediate iMpurity II may be used in the research and development of other related compounds with potential therapeutic applications in the treatment of various diseases and conditions.

Upstream product

• 64-17-5 ethanol 
• 1025972-83-1 4-acetyl-2-propylimidazole-5-carboxylic acid 
• 144690-06-2 4-acetyl-2-propylimidazole-5-carbonitrile 
• 51802-42-7 2-propylimidazole-4,5-dicarbonitrile 

Downstream Products

• 172875-53-5 ethyl 4-(1-hydroxy-1-methylpropyl)-2-propylimidazole-5-carboxylate 
• 172876-11-8 3-(2'-Carboxy-biphenyl-4-ylmethyl)-5-ethyl-2-propyl-3H-imidazole-4-carboxylic acid ethyl ester 
• 172875-77-3 3-(2'-Carboxy-biphenyl-4-ylmethyl)-5-(1-hydroxy-1-methyl-propyl)-2-propyl-3H-imidazole-4-carboxylic acid ethyl ester 
• 172876-07-2 3-(2'-tert-Butoxycarbonyl-biphenyl-4-ylmethyl)-5-ethyl-2-propyl-3H-imidazole-4-carboxylic acid ethyl ester 
• 172875-66-0 3-(2'-tert-Butoxycarbonyl-biphenyl-4-ylmethyl)-5-(1-hydroxy-ethyl)-2-propyl-3H-imidazole-4-carboxylic acid ethyl ester 
• 144689-43-0 ethyl 4-(1-hydroxyethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate 
• 172875-55-7 3-(2'-tert-Butoxycarbonyl-biphenyl-4-ylmethyl)-5-(1-hydroxy-1-methyl-propyl)-2-propyl-3H-imidazole-4-carboxylic acid ethyl ester 
• 1026598-44-6 Oxalic acid 1-[1-(2'-tert-butoxycarbonyl-biphenyl-4-ylmethyl)-5-ethoxycarbonyl-2-propyl-1H-imidazol-4-yl]-ethyl ester ethyl ester 
• 172875-72-8 5-(1-Hydroxy-ethyl)-2-propyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 

Relevant articles and documents

ANGIOTENSIN II ANTAGONIST 1-BIPHENYLMETHYLIMIDAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE

Compounds of the following formula (I) or the formula (I) p : STR1 wherein R 1 is alkyl or alkenyl; R 2 and R 3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R 4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula--SiR a R b R c, in which R a, R b and R c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R 5 is carboxy or--CONR 8 R 9, wherein R 8 and R 9 hydrogens or alkyl, or R 8 and R 9 together form alkylene; R 6 is hydrogen, alkyl, alkoxy or halogen; R. sup.7 is carboxy or tetrazol-5-yl; R p. sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R p 2 is a single bond, alkylene or alkylidene; R p 3 and R p 4 are each hydrogen or alkyl; R. sub.p 6 is carboxy or tetrazol-5-yl; and X p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.